As part of the study, which was supported by Novartis, the researchers evaluated the Novartis Social Business programme, which offers a portfolio of non-communicable disease (NCD) medicines at a wholesale price of $1 per treatment per month.

Boston University School of Public Health global health lead author Peter Rockers said: “It is our hope that the evidence generated by this study will inform Novartis’ efforts to improve their programme going forward.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

“The study also contributes to the public evidence base on strategies for improving access to medicines globally. Rigorous measurement and transparent reporting should be standard for all pharmaceutical industry efforts to improve access.”

The researchers evaluated the effect of the first 15 months of the Novartis Access programme in Kenya for the study.

As part of the study, the researchers compared NCD medicines access during that period in four Kenyan counties with access in four other counties with similar demographics and health variables.

They found that the programme increased the availability of the hypertension drug amlodipine and the type-2 diabetes drug metformin in health facilities.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Study co-author Veronika Wirtz said: “Access programmes operate within complex health systems and reducing the wholesale price of medicines might not always or immediately translate to improved patient access.”

Furthermore, the researchers found, while patients were usually diagnosed with an NCD in the public or faith-based mission sector, most of them obtained their medicines from the private sector.